Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia 6Myelodysplastic Syndromes 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Anemia, Refractory, with Excess of Blasts 2Neutropenia 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Hematologic Diseases 1Blast Crisis 1Anemia, Refractory 1

Interventions

Cyclophosphamide 23Cyclosporine 17Busulfan 16fludarabine phosphate 14Radiotherapy 12Mycophenolic Acid 12Cord Blood Stem Cell Transplantation 12Antilymphocyte Serum 12Peripheral Blood Stem Cell Transplantation 11Whole-Body Irradiation 10Methotrexate 8Methylprednisolone 7Tacrolimus 6Filgrastim 6Melphalan 5fludarabine 4sargramostim 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Cytarabine 3Cyclosporins 3merphos 2Transplantation 2Thiotepa 2Thalidomide 2Arsenic Trioxide 2vatalanib 1paricalcitol 1lintuzumab 1gamma-Globulins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anemia, Refractory × lintuzumab × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡